OBIO
NASDAQOrchestra BioMed Holdings Inc.
News25/Ratings9
News · 26 weeks51+100%
2026-03-012026-08-23
Mix2890d
- Insider17(61%)
- SEC Filings6(21%)
- Other4(14%)
- Market1(4%)
Latest news
25 items- PROrchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare ConferenceNEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the Wells Fargo 21st Annual Healthcare Conference on Thursday, Sept. 10, 2026 at 1:30pm ET and will also host one-on-one meetings with investors that day and on Wednesday, Sept. 9. A live webcast of the event will be accessible through Orchestra BioMed’s Investor Relations website and will be available for replay following the event. About Orchestra BioMedOrchestra BioMed is a b
- INSIDERDirector Mack John Prosper covered exercise/tax liability with 4,885 shares, decreasing direct ownership by 7% to 66,544 units (SEC Form 4) (tax liability)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERDirector Fain Eric S covered exercise/tax liability with 5,145 shares (SEC Form 4) (withholding obligation)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERDirector Pacitti David covered exercise/tax liability with 3,761 shares, decreasing direct ownership by 6% to 54,750 units (SEC Form 4) to satisfy withholding tax4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- PROrchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business UpdatesThe BACKBEAT global pivotal trial ("BACKBEAT Trial"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.Virtue pivotal trial is advancing with further site activations and patient enrollments. $110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both the AVIM Therapy and Virtue SAB programs. NEW HOPE, Pa., Aug. 10, 20
- SECSEC Form 10-Q filed by Orchestra BioMed Holdings Inc.10-Q - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
- INSIDEROfficer Sherman Darren sold $61,350 worth of shares (15,000 units at $4.09) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,154,327 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- SECSEC Form 144 filed by Orchestra BioMed Holdings Inc.144 - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
- INSIDEROfficer Sherman Darren sold $64,050 worth of shares (15,000 units at $4.27) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,169,327 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- SECSEC Form 144 filed by Orchestra BioMed Holdings Inc.144 - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
- PROrchestra BioMed Joins Russell 3000® and Russell 2000® IndexesNEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today that it has joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the 2026 Russell indexes reconstitution, effective after the U.S. market close on June 26, 2026. The Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place until the ne
- INSIDERDirector Fain Eric S was granted 17,327 shares and covered exercise/tax liability with 4,261 shares (SEC Form 4) to satisfy tax liability4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERDirector Pacitti David was granted 17,327 shares and covered exercise/tax liability with 3,784 shares, increasing direct ownership by 30% to 58,511 units (SEC Form 4) (for tax liability)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERDirector Cleary Chris covered exercise/tax liability with 3,510 shares, decreasing direct ownership by 10% to 33,391 units (SEC Form 4) to cover withholding tax4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERDirector Connealy Pamela Ann was granted 17,327 shares, increasing direct ownership by 36% to 66,038 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERSEC Form 4 filed by Director Aryeh Jason4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERDirector Mack John Prosper was granted 34,653 shares and covered exercise/tax liability with 3,510 shares, increasing direct ownership by 77% to 71,429 units (SEC Form 4) to satisfy withholding obligation4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- SECOrchestra BioMed Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
- SECSEC Form S-8 filed by Orchestra BioMed Holdings Inc.S-8 - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
- NEWSSidoti Events, LLC's June Small-Cap Virtual ConferenceNEW YORK, NY / ACCESS Newswire / June 16, 2026 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day June Small-Cap Virtual Investor Conference taking place Wednesday and Thursday, June 17-18, 2026. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.Presentation Schedule*All Times EDTWednesday, June 17, 2026 (Day 1)8:30-9:00Avalon Advanced Materials (AVL)Aurora Mobile (JG)9:15-9:45Onity Group (ONIT)*****10:00-10:30Charles River Associates (CRAI)*****10:45-11:15RLJ Lodging Trust (RLJ)*****11:30-12:00GigaCloud Technology (GCT)Cibus (CBUS)12:1
- INSIDERChief Financial Officer Taylor Andrew Lawrence covered exercise/tax liability with 36,352 shares, decreasing direct ownership by 6% to 593,065 units (SEC Form 4) to satisfy tax liability4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDEROfficer Hochman David P covered exercise/tax liability with 6,566 shares, decreasing direct ownership by 0.31% to 1,060,746 units (SEC Form 4) (tax withholding)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDEROfficer Hochman David P bought $19,150 worth of shares (5,000 units at $3.83), increasing direct ownership by 0.47% to 1,064,029 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDEROfficer Sherman Darren sold $58,050 worth of shares (15,000 units at $3.87) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,184,327 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- PROrchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on June 1, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 85,500 shares of the Company's common stock to five newly hired employees. The awards were granted pursuant to the Orchestra Biomed Holdings, Inc. 2025 New Hire Inducement Plan as an inducement material to each new employee entering employment with Or
OBIO FAQ
6 questionsWhere does OBIO stock trade?
Orchestra BioMed Holdings Inc. (OBIO) is listed on NASDAQ.What sector and industry is OBIO in?
Orchestra BioMed Holdings Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.When did Orchestra BioMed Holdings Inc. go public?
Orchestra BioMed Holdings Inc. (OBIO) completed its IPO in 2020.What are analysts saying about OBIO?
Orchestra BioMed Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy with a $1500.00 price target on 2025-12-10. Recent price targets range from $1200.00 to $1600.00.What companies are similar to OBIO?
Notable peers in the same industry include PM (Philip Morris International Inc), BTI (British American Tobacco Industries p.l.c.), MO (Altria Group Inc.), DFTX (Definium Therapeutics Inc.), CGC (Canopy Growth Corporation). Compare OBIO side-by-side with any of them on Quantisnow.How can I track OBIO on Quantisnow?
Quantisnow aggregates Orchestra BioMed Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OBIO to receive live email and push alerts on every new disclosure.